Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Thursday 30 July, 2020

Verona Pharma plc

Verona Pharma plc: TR-1: Standard form for notification of major holdings

Verona Pharma plc: TR-1: Standard form for notification of major holdings

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) --

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Verona Pharma plc
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an “X” if appropriate)
Non-UK issuer  
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify) iii :  
3. Details of person subject to the notification obligation iv
Name Abingworth LLP
Abingworth Bioventures VI LP
 
City and country of registered office (if applicable) London, UK
4. Full name of shareholder (s) (if different from 3.) v
Name State Street (Nominees) Limited (as nominee for Abingworth Bioventures VI LP)
 
City and country of registered office (if applicable) London, UK
5. Date on which the threshold was crossed or reached vi : 22/07/2020
6. Date on which issuer notified (DD / MM / YYYY): 30/07/2020
7. Total positions of person (s) subject to the notification obligation
  % of voting rights
attached to shares
(total of 8. A)
% of voting rights
through financial
instruments
(total of 8.B 1 + 8.B 2)
Total of both in%
(8.A + 8.B)
Total number of
voting rights of
issuer vii
Resulting situation on the date on which threshold was crossed or reached
 
4.75   4.75 414,278,294
Position of previous notification (if
applicable)
 
6.90   6.90  



8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class / type of
shares

ISIN code (if possible)
Number of voting rights ix % of voting rights
Direct
(Art. 9 of Directive
2004/109 / EC) (DTR5.1)
Indirect
(Art. 10 of Directive
2004/109 / EC) (DTR5.2.1)
Direct
(Art. 9 of Directive
2004/109 / EC) (DTR5.1)
Indirect
(Art. 10 of Directive
2004/109 / EC) (DTR5.2.1)
Verona Pharma plc
GB00BYW2KH80
5p Ords
 
1   less than 0.01  
Verona Pharma plc US9250501064
ADSs
19,660,000   4.75  
         
SUBTOTAL 8. A 19,660,001 4.75
 

 
B 1: Financial Instruments according to Art. 13 (1) (a) of Directive 2004/109 / EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date
x
Exercise /
Conversion Period
xi
Number of voting rights
that may be acquired if
the instrument is
exercised / converted.
% of voting rights
         
         
         
    SUBTOTAL 8. B 1    
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13 (1) (b) of Directive 2004/109 / EC (DTR5.3.1.1 (b))
Type of financial
instrument
Expiration
date
x
Exercise /
Conversion
Period
xi
Physical or
cash
settlement xii
Number of
voting rights
% of voting rights
           
           
           
      SUBTOTAL 8.B.2    
 


9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking (s) holding directly or indirectly an interest in the (underlying) issuer xiii  
Full chain of controlled undertakings through which the voting rights and / or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary) X
Name xv % of voting rights if it
equals or is higher
than the notifiable
threshold
% of voting rights
through financial
instruments if it equals
or is higher than the
notifiable threshold
Total of both if it
equals or is higher
than the notifiable threshold
Abingworth LLP 4.75   4.75
Abingworth Bioventures VI LP less than 0.01   less than 0.01
       
       
       
 
10. In case of proxy voting, please identify:
Name of the proxy holder  
The number and% of voting rights held  
The date until which the voting rights will be held  
 
11. Additional information xvi
Abingworth Bioventures VI LP (which holds 19,660,001 shares in the company (4.75%)) is managed by Abingworth LLP. 
 

 


Place of completion Outside a trading venue
Date of completion 30 July 2020

For further information, please contact:

Verona Pharma plc Tel: +44 (0) 20 3283 4200
David Zaccardelli, Chief Executive Officer [email protected]
Victoria Stewart, Director of Communications  
   
N + 1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7496 3000
Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)  
Tom Salvesen (Corporate Broking)

a d v e r t i s e m e n t